Great Lakes sells Holywell site to Ian Schott Development
Ian Shott Development (ISD), a subsidiary of Ian Shott Enterprises, has acquired Great Lakes Fine Chemicals' Holywell business for an undisclosed sum.
Ian Shott Development (ISD), a subsidiary of Ian Shott Enterprises, has acquired Great Lakes Fine Chemicals' Holywell business for an undisclosed sum.
The group also comprises chemical and pharmaceutical industry consultants Ian Shott Associates, and process engineering design, build and construction firm Ian Shott Technology, based in Durham in the UK.
The new business will offer a range of services and technologies from r&d to small-scale manufacture of pharmaceutical and speciality intermediates and ingredients. In addition, ISD will seek to exploit fully the intellectual property inherited from NSC Technologies, which Great Lakes had previously acquired from Monsanto. The site was recently the focus of a US$8m investment programme that saw the construction of new laboratories, additional cGMP facilities and infrastructure improvements.
According to group founder and ISD chairman Ian Schott, the company will be looking to build further business in the contract research sector, using the two new Class 100,000 laboratories at Holywell. These laboratories are supported by two r&d labs and a large analytical facility. Production of Active Pharmaceutical Ingredients (APIs) is also conducted in a cGMP facility, which features 19 reactors up to 1300-litre capacity, while two non-cGMP plants have reactors up to 4500 litres.
Shott has held senior executive positions in the international pharmaceutical and fine chemicals industries for some 20 years and has worked in the UK, France, Switzerland and US. Most recently he was president of Rhodia ChiRex's manufacturing division, having previously held posts at Lonza and Zeneca.
'We are delighted to complete the acquisition which marks a new era in the development of this recently upgraded facility,' he said. 'We will actively pursue new business and academic collaborations to capitalise on our distinctive expertise in unnatural amino acid technologies and asymmetric synthesis while focusing on the special needs of our customers.'